Aspirin failure in patients presenting with acute cerebrovascular ischaemiaFinancial support: The study was funded by NHS Grampian Endowments Stroke Fund. The Royal Embassy of Saudi Arabia funded Dr Halawani’s postgraduate studentship.
Received: 28 January 2011
Accepted after major revision: 08 April 2011
25 November 2017 (online)
Aspirin is the most commonly used antiplatelet drug for prevention of ischaemic stroke. In order to determine the prevalence and nature of aspirin failure, we studied 51 adults admitted with suspected ischaemic stroke and already prescribed daily aspirin. Within 48 hours (h) of onset, blood and urine samples were collected to assess platelet aggregation, activation and aspirin response by a range of methods. All tests were then repeated on a second sample taken 24 h after witnessed administration of 75 mg or 150 mg aspirin. At entry to the study, incomplete response to aspirin, measured by arachidonic acid (AA)-stimulated platelet aggregation, was found in 43% of patients. Following in-hospital aspirin administration, there was a significant decrease in AA-aggregation (p=0.001) suggesting poor adherence to therapy prior to admission. However, residual aggregation (10–15%) persisted in 11 subjects – suggesting alternative causes. In incomplete responders on admission, platelet aggregation with adenosine diphosphate (ADP) was significantly higher compared with responders (p<0.05) but there were no significant differences in collagen aggregation, platelet fibrinogen binding or P-selectin expression, plasma von Willebrand factor, fibrinogen, high-sensitivity C-reactive protein, or the urinary metabolite, 11-dehydro-TxB2. Incomplete platelet inhibition is common around the time of acute cerebrovascular ischaemic events in patients prescribed aspirin. Up to 50% of these observations appear due to incomplete adherence to aspirin therapy. Intervention studies are required to determine the clinical relevance of measured platelet response to aspirin in terms of outcome, and the effectiveness of improved pharmacotherapy for stroke prevention.
* Current address: Department of Geriatric and General Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland.
- 1 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, strokes in high-risk patients. Br Med J 2002; 324: 71-86.
- 2 Hankey GJ, Eikelboom JW. Aspirin Resistance may be a cause of recurrent vascular events in patients taking aspirin. Br Med J 2004; 328: 477-479.
- 3 Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5: 230-237.
- 4 Grove EL, Hvas A-M, Johnsen HL. et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253.
- 5 Lordkipanidzé M, Pharand C, Schampaert E. et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
- 6 Michelson AD, Cattaneo M, Eikelboom JW. et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309-1311.
- 7 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
- 8 Gum P, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
- 9 Gengo FM, Rainka M, Robson M. et al. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J Clin Pharmacol 2008; 48: 335-343.
- 10 O’Connor PJ. Improving medication adherence. Arch Intern Med 2006; 166: 1802-1804.
- 11 Rajagopalan S, Ford I, Bachoo P. et al. Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery. J Thromb Haemost 2007; 5: 2028-2035.
- 12 Webster SE, Payne DA, Jones CI. et al. Anti-platelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy. J Vasc Surg 2004; 40: 463-468.
- 13 Alberts M, Bergman D, Molner E. et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004; 35: 175-178.
- 14 Berrouschot J, Schwetlick B, von Twickel G. et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006; 113: 31-35.
- 15 Helgason CM, Bolin KM, Hoff JA. et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-2336.
- 16 Harrison P, Segal H, Blasbery K. et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005; 36: 1001-1005.
- 17 Komiya T, Kudo M, Urabe T. et al. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Stroke 1994; 25: 2337-2342.
- 18 Gurbel PA, Bliden KP, DiChiara J. et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164.
- 19 Frelinger AL, Furman M, Linden M. et al. Residual arachidonic-acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway. Circulation 2006; 113: 2888-2896.
- 20 Frelinger AL, Li Y, Linden M. et al. Aspirin “resistance”: Role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 6: 2035-2044.
- 21 Maree A, Fitzgerald D. Variable platelet response to aspirin and clopidogrel. Circulation 2007; 115: 2196-2207.
- 22 Gum P, Kottke-Marchant K, Poggio ED. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
- 23 Harrison P, Segal H, Silver L. et al. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008; 19: 119-124.
- 24 Meiklejohn DJ, Vickers MA, Morrison ER. et al. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol 2001; 112: 621-631.
- 25 Perneby C, Wallen HN, Rooney C. et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658.
- 26 McCabe DJ, Harrison P, Sidhu PS. et al. Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. Br J Haematol 2004; 126: 861-869.
- 27 Grove EL, Hvas AM, Mortensen SB. et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9: 185-191.
- 28 Lordkipanidzé M. Why an aspirin a day no longer keeps the doctor away. Thromb Haemost 2011; 105: 209-210.
- 29 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
- 30 Snoep JD, Hovens M, Eikenboom J. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch Intern Med 2007; 167: 1593-1599.
- 31 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
- 32 Eikelboom JW, Hankey GJ, Thom J. et al. on behalf of the CHARISMA Investigators. Incomplete inhibition of thromboxane biosynthesis by acetyl salicylic acid: Determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-1712.
- 33 FitzGerald GA, Oates JA, Hawiger J. et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-688.
- 34 Ohmori T, Yatomi Y, Nonaka T. et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006; 4: 1271-1278.
- 35 Cattaneo M. Laboratory detection of ‘aspirin resistance’: what test should we use (if any)?. Eur Heart J 2007; 28: 1673-1675.